Eye Conditions & Diseases for Current Trials
DIABETIC RETINOPATHY
The New Day Study
A Study of Intraviteral ILUVIEN Implant as Baseline Therapy in Patients With Diabetic Macular Edema (DME).
Comparing Aflibercept to Iluvien 0.19 MG Drug Implant
Study is for 18 months with monthly visits.
- Male or females patient ≥18 years of age at the time of consent.
- Diagnosis of Type 1 or Type 2 Diabetes
- Must have CI-DME confirmed by Spectral Domain Ocular Coherence Tomography
- Treatment Naive
The Glim/Glimmer Study
A Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME
Comparing Aflibercept to KSI-301 to Sham Procedure.
Study is for 2 years with Monthly treatments.
- A1C ≤12 %
- Diagnosis of Type 1 or Type 2 Diabetes Mellitus
- Treatment Naive
The Glow Study
A Phase 3, Prospective, Randomized, Double-masked, Sham Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Participants with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR).
Comparing Aflibercept to KSI-301 to Sham Procedure.
Study is for 2 years with Monthly treatments.
- Nonproliferative Diabetic Retinopathy with no DME
- DRSS Levels 47 or 53
- Treatment Naïve
MACULAR DEGENERATION
The Golden Study
Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geography Atrophy (GA) Secondary to Age-Related Macular Degeneration.
Comparing IONIS-FB-Lrx versus Placebo (sterline saline .09%) subcutaneous treatment.
Study is for one year with monthly visits.
- Be at least 50 years of age
- Have a medical diagnosis of AMD in at least one eye
PROLIFERATIVE VITREORETINOPATHY
The Guard Study
A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
Comparing Standard Surgical Care to Intravitreal Methotrexate 0.8%
Study is 16 weeks. Patients can be seen weekly or monthly depending on which arm they randomize in.
- Diagnosis of Retinal Detachment with PVR in either eye
- Subject is 18 years or older of any gender or race
RETINAL VEIN OCCLUSION
The Beacon Study
A Prospective, Randomized, Double-Masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-Naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).
Study is for Approximately two years with monthlyappointments.
• Male or Female ≥ 18 years of age
• Have a confirmed diagnosis of Retinal Vein Occlusion (RVO)
• Decrease in vision due to the Retinal Vein Occlusion
OCULAR SURFACE DISEASE
The Surf-200 Study
A Multi-Center, Randomized, Double-Masked, Dose-Ranging Study To Compare The Ocular Safety, Tolerability, And Efficacy Of SURF-200 Ophthalmic Solution (0.02% Betamethasone Sodium Phosphate) To Vehicle In Subjects With A Diagnosis of Dry Eye Disease And Experiencing An Episodic Flare Up.
The study is approximately 10 weeks long.
• Diagnosis of Dry Eye Syndrome
• Subjects who are ≥ 18 years of age
• Schirmer’s test greater than 1 mm but less than or equal to 12 mm in the study eye.
We’ll Email You!
If you’d like us to send you more information on these eye conditions and their
clinical trials we’re conducting, just fill out this form.
